Literature DB >> 15452212

Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus.

David A Coil1, A Dusty Miller.   

Abstract

The envelope protein from vesicular stomatitis virus (VSV) has become an important tool for gene transfer and gene therapy. It is widely used mainly because of its ability to mediate virus entry into all cell types tested to date. Consistent with the broad tropism of the virus, the receptor for VSV is thought to be a ubiquitous membrane lipid, phosphatidylserine (PS). However, the evidence for this hypothesis is indirect and incomplete. Here, we have examined the potential interaction of VSV and PS at the plasma membrane in more detail. Measurements of cell surface levels of PS show a wide range across cell types from different organisms. We demonstrate that there is no correlation between the cell surface PS levels and VSV infection or binding. We also demonstrate that an excess of annexin V, which binds specifically and tightly to PS, does not inhibit infection or binding by VSV. While the addition of PS to cells does allow increased virus entry, we show that this effect is not specific to the VSV envelope. We conclude that PS is not the cell surface receptor for VSV, although it may be involved in a postbinding step of virus entry.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452212      PMCID: PMC521854          DOI: 10.1128/JVI.78.20.10920-10926.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Improved retroviral vectors for gene transfer and expression.

Authors:  A D Miller; G J Rosman
Journal:  Biotechniques       Date:  1989-10       Impact factor: 1.993

2.  Outside-inside translocation of aminophospholipids in the human erythrocyte membrane is mediated by a specific enzyme.

Authors:  A Zachowski; E Favre; S Cribier; P Hervé; P F Devaux
Journal:  Biochemistry       Date:  1986-05-06       Impact factor: 3.162

3.  Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers.

Authors:  H A Andree; C P Reutelingsperger; R Hauptmann; H C Hemker; W T Hermens; G M Willems
Journal:  J Biol Chem       Date:  1990-03-25       Impact factor: 5.157

4.  Location of tryptophans in membrane-bound annexins.

Authors:  P Meers
Journal:  Biochemistry       Date:  1990-04-03       Impact factor: 3.162

5.  Relationship between annexin V tryptophan exposure, calcium, and phospholipid binding.

Authors:  P Meers; T Mealy
Journal:  Biochemistry       Date:  1993-05-25       Impact factor: 3.162

6.  Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes.

Authors:  C Pigault; A Follenius-Wund; M Schmutz; J M Freyssinet; A Brisson
Journal:  J Mol Biol       Date:  1994-02-11       Impact factor: 5.469

7.  Phospholipid binding of annexin V: effects of calcium and membrane phosphatidylserine content.

Authors:  J F Tait; D Gibson
Journal:  Arch Biochem Biophys       Date:  1992-10       Impact factor: 4.013

8.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus.

Authors:  A D Miller; J V Garcia; N von Suhr; C M Lynch; C Wilson; M V Eiden
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

9.  Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity.

Authors:  L V Rao; J F Tait; A D Hoang
Journal:  Thromb Res       Date:  1992-09-01       Impact factor: 3.944

10.  Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family.

Authors:  J F Tait; D Gibson; K Fujikawa
Journal:  J Biol Chem       Date:  1989-05-15       Impact factor: 5.157

View more
  82 in total

1.  Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential.

Authors:  Michael Zasloff; A Paige Adams; Bernard Beckerman; Ann Campbell; Ziying Han; Erik Luijten; Isaura Meza; Justin Julander; Abhijit Mishra; Wei Qu; John M Taylor; Scott C Weaver; Gerard C L Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Viral infection: Moving through complex and dynamic cell-membrane structures.

Authors:  Jonathan Barroso-González; Laura García-Expósito; Julià Blanco; Agustín Valenzuela-Fernández; Isabel Puigdomènech; Laura de Armas-Rillo; José-David Machado
Journal:  Commun Integr Biol       Date:  2011-07-01

Review 3.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

4.  Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins.

Authors:  Yoon-Sang Kim; Matthew M Wielgosz; Phillip Hargrove; Steven Kepes; John Gray; Derek A Persons; Arthur W Nienhuis
Journal:  Mol Ther       Date:  2010-04-06       Impact factor: 11.454

5.  Endoplasmic reticulum chaperone gp96 is essential for infection with vesicular stomatitis virus.

Authors:  Stuart Bloor; Jonathan Maelfait; Rebekka Krumbach; Rudi Beyaert; Felix Randow
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

Review 6.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

7.  Use of replication restricted recombinant vesicular stomatitis virus vectors for detection of antigen-specific T cells.

Authors:  Nelson B Moseley; Oskar Laur; Chris C Ibegbu; Gilbert D Loria; Gini Ikwuenzunma; Himangi R Jayakar; Michael A Whitt; John D Altman
Journal:  J Immunol Methods       Date:  2011-10-08       Impact factor: 2.303

8.  Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Authors:  Sébastien A Felt; Gaith N Droby; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

9.  Anionic lipids are required for vesicular stomatitis virus G protein-mediated single particle fusion with supported lipid bilayers.

Authors:  Pedro M Matos; Mariana Marin; Byungwook Ahn; Wilbur Lam; Nuno C Santos; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2013-03-14       Impact factor: 5.157

10.  LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus.

Authors:  Danit Finkelshtein; Ariel Werman; Daniela Novick; Sara Barak; Menachem Rubinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.